Bio-Rad Laboratories, Inc. Class A Common Stock vs CDW Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while CDW Corp. trades at $144.5 (market cap $18.44B). The key difference: CDW Corp. is far larger — about 2.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and CDW Corp. pays a 1.75% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | CDW | |
|---|---|---|
Market Cap | $8.02B | $18.44B |
Sector | Health | Technology |
52-Week High | $339.75 | $182.18 |
52-Week Low | $241.71 | $99.30 |
Enterprise Value | $7.84B | $23.65B |
Dividend Yield | — | 1.75% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →